Tag Archives: SRPT

Top 5 Undervalued Stocks To Buy For 2019

Gilead Sciences (GILD) is a large capitalization pharmaceutical and biotechnology company best known for its HIV and HCV (hepatitis C) therapies.

After Gilead showed it could generate large amounts of revenue from new, highly effective cures for HCV, its stock price rose to a peak of $123.57 per share in June 2015. That was quite a climb upward from $37.16 per share at the beginning of 2013, but since then the stock price, although volatile, has drifted mainly downward.

Harvoni pill. Source: Gilead.com

Many analysts and financial journalists, including this author,....More>>>

Top 10 Value Stocks To Invest In Right Now

Whole Foods Market (NASDAQ:WFM) has had a bad time on the market over the past couple of months, losing over 16% of its value on the back of a weak financial performance in its last reported quarter. But, in my opinion, the recent drop in Whole Foods’ shares is an opportunity to buy more of the stock since there are tangible improvements being witnessed across Whole Foods’ operations as discussed in this article. Let’s take a look.

Sales building initiatives are delivering results

Whole Foods Market’s focus on improving its sales is delivering results, slowly....More>>>

Sarepta Therapeutics (SRPT) Hits New 1-Year High and Low on Analyst Upgrade

Sarepta Therapeutics (NASDAQ:SRPT)’s share price reached a new 52-week high and low on Wednesday after Leerink Swann raised their price target on the stock from $88.00 to $121.00. Leerink Swann currently has an outperform rating on the stock. Sarepta Therapeutics traded as low as $95.67 and last traded at $94.81, with a volume of 42782 shares trading hands. The stock had previously closed at $92.22.

A number of other equities research analysts also recently commented on the stock. Credit Suisse Group lifted their price target on shares of Sarepta Therapeutics from $81.00 to $100.00....More>>>

Sarepta Therapeutics (SRPT) Hits New 1-Year High and Low on Analyst Upgrade

Sarepta Therapeutics (NASDAQ:SRPT)’s share price reached a new 52-week high and low on Wednesday after Leerink Swann raised their price target on the stock from $88.00 to $121.00. Leerink Swann currently has an outperform rating on the stock. Sarepta Therapeutics traded as low as $95.67 and last traded at $94.81, with a volume of 42782 shares trading hands. The stock had previously closed at $92.22.

A number of other equities research analysts also recently commented on the stock. Credit Suisse Group lifted their price target on shares of Sarepta Therapeutics from $81.00 to $100.00....More>>>

Top 5 Safest Stocks For 2018

Kimberly-Clark Corp. (NYSE:KMB) has provided investors with reliable income increases for decades.

In fact, the company is one of the 51 Dividend Aristocrats, which can all be seen here.

Kimberly-Clark pays one of the safest dividends in the market, yields close to 3%, offers mid-single-digit payout growth and sells recession-resistant products.

All of these investment qualities are appealing for retired investors living on dividends.

Like many other large consumer brand multinationals however, Kimberly-Clark is battling foreign currency headwinds, slower growth in....More>>>